









Markets
/
Stocks
/
nasdaq-omcl
/

Omnicell Inc

OMCL



View Detailed Chart

45.300USD

-0.620-1.35%

Close 12/31, 16:00（ET）Quotes delayed by 15 min

2.03BMarket Cap

104.80P/E TTM



Omnicell Inc

45.300

-0.620-1.35%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.35%

5 Days

-1.05%

1 Month

+25.42%

6 Months

+51.35%

Year to Date

+1.75%

1 Year

+1.75%

View Detailed Chart

TradingKey Stock Score of Omnicell Inc

Currency: USD Updated: 2025-12-30

Key Insights

Omnicell Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 9/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 48.17.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Omnicell Inc's Score

Industry at a Glance

Industry Ranking

9 / 207

Overall Ranking

56 / 4560

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

48.167

Target Price

+10.60%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Omnicell Inc Highlights

StrengthsRisks

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.11B.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 106.23, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.76M shares, decreasing 13.49% quarter-over-quarter.

Held by Barrow Hanley

Star Investor Barrow Hanley holds 100.00 shares of this stock.